J&J sales near $25B for Q1, with sol­id on­col­o­gy, im­munol­o­gy gains

John­son & John­son tout­ed gains in its phar­ma­ceu­ti­cal busi­ness that were dri­ven by on­col­o­gy and im­munol­o­gy drugs, but it was un­ex­pect­ed gains on Covid-19 vac­cine sales out­side of the US that helped it beat Q1 ex­pec­ta­tions.

J&J record­ed $747 mil­lion in sales of its Covid vac­cine dur­ing the first quar­ter, up 63% over the same quar­ter last year, help­ing bump its Janssen phar­ma di­vi­sion by 4.2% to $13.4 bil­lion in sales.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER